Arcas News
In 2011, we significantly expanded our physician engagement services. Working with several clients, we have introduced new CME opportunities and practice management tools to our MDoutlook network of 62,000 validated cancer providers. Our approach focuses on driving new opportunities to the MDoutlook members that will enhance their ability to improve patient care.
A particular success story stands out. One of our CME clients wanted to broaden its reach into the oncology and hematology physician community in the United States. Arcas developed a campaign with a series of targeted emails to physicians, matching the topic of the programs offered to the physician’s clinical interest and practice setting. The CME programs included webinars, downloadable slide sets, monographs, access to live programs and much more. In close coordination with the client’s own marketing efforts, we boosted the client’s outreach into the community by more than 500%!
Here is a slide that the client presented to their management team to discuss the success of the program. Our work started in January 2011 and continued through the year.
To put this into perspective: in 2010, our client had received fewer than 20,000 views and 10,000 downloads of their programs…
If you have a specific oncology intelligence or physician engagement need - big or small, complex or more straightforward, focused on a country or with a global scope, please contact us to discuss your intelligence needs.
May 9th, 2012
A fun fact: since the launch of MDoutlook late 2008 we have consistently been ranked by Google as the #1 site for oncology intelligence.
In the same period, we have expanded our network to more than 62,000 cancer treaters globally, have delivered over 150 proprietary and customized research studies covering 17 distinct cancer types.
And we proudly count 6 of the top-10 pharmaceutical companies, and numerous biotech, diagnostic and medical device companies as our clients.
If you have a specific oncology intelligence need – big or small, complex or less ambiguous, focused on a particular country or a larger region, please contact us to discuss your intelligence needs.
We look forward to enhancing your understanding of the oncology landscape in 2012!
The Arcas Group and MDOUTLOOK Teams
March 27th, 2012
As we continue to grow and to enhance our services and deliverables to our clients, we are hiring for a Director, Account Services. If you, or someone you know, qualify for this demanding and rewarding position, and wish to join a fast-growing organization with innovative offerings, please contact our President, Jan Heybroek via email.
Qualified candidates only, please. Solicitation by recruiters not needed or appreciated.
February 10th, 2012
MDOUTLOOK, our exclusive web-based disease intelligence resource, provides the insight critical to reaching your commercialization goals for specialty diseases. Our customized approach engages over 60,000 multi-disciplinary specialists active in oncology care worldwide, as part of a larger database of more than 250, 000 validated and verified healthcare providers.
As confirmed at the recent Pharma Market Research Meeting in Parsipanny, it is becoming clear that both industry and market research experts agree a paradigm shift is needed in the way that market research is performed and what it delivers. The meeting was all about delivering actionable insight to clients using fresh methodologies and approaches. This is exactly what MDOUTLOOK was set up to do and has been providing to our clients.
We want to share with you a sample of the actionable insight we have compiled in 2011 - complimentary reports are available for immediate download by clicking on the links below:
* Global Clinical Impact of Bevacizumab Revocation in metastatic Breast Cancer
* Recent Developments in the Treatment of Myelofibrosis
* New Clinical Data in Pancreatic Neuroendocrine Tumors
* ASCO 2011: Immediate Impact on Clinical Practice in NSCLC
* ASCO 2011: Immediate Impact on Clinical Practice in Melanoma
* ASCO 2011: Immediate Impact on Clinical Practice in Gastrointestinal Cancer
Explore MDOutlook to discover the advantage of total oncology intelligence. You can preview the MDOUTLOOK advantage here or contact us to discuss your intelligence needs.
We look forward to enhancing your understanding of the oncology landscape in 2012!
The Arcas Group and MDOUTLOOK Teams
February 10th, 2012
Earlier this month, the ASCO Post featured recent research and analysis from MDoutlook. The article focused on the downstream implications of the FDA revoking the breast cancer indication for bevacizumab on Friday November 18, 2011.
MDoutlook was the first source to report on the global clinical impact of this news through our unique and proprietary oncology intelligence platform now reaching more than 62,000 cancer treaters globally. The research was conducted over a 3-day period directly following the decision with the results from 232 oncologists posted on Wednesday, November 23, 2011 in OBR Daily.
You can read the ASCO Post article here and a link to the original article in OBR is provided here.
For more information on our capabilities to assess, analyze and report on market-moving events in specialty diseases, and on our customized research programs please contact us at info@mdoutlook.com, 888.368.8566 or internationally +1.404.496.4136. A quick overview of our capabilities can be download through this download: MDoutlook capabilities.
January 23rd, 2012
On behalf of the Arcas Group team, we wish you an enjoyable and relaxing holiday season!
In preparation for a prosperous 2012, please accept our gift of complimentary MDOUTLOOK® Analysis Reports.
MDOUTLOOK, our exclusive web-based platform, provides the marketplace insight critical to reaching your commercialization goals. Our customized approach engages over 60,000 multi-disciplinary specialists active in oncology care worldwide.
Complimentary 2011 Analysis Reports - immediately available for download:
* Global Clinical Impact of Bevacizumab Revocation in metastatic Breast Cancer
* Recent Developments in the Treatment of Myelofibrosis
* New Clinical Data in Pancreatic Neuroendocrine Tumors
* ASCO 2011: Immediate Impact on Clinical Practice in NSCLC
* ASCO 2011: Immediate Impact on Clinical Practice in Melanoma
* ASCO 2011: Immediate Impact on Clinical Practice in Gastrointestinal Cancer
Explore MDOutlook to discover the advantage of total oncology intelligence. You can preview the MDOUTLOOK advantage here or contact us at info@mdoutlook.com to discuss your intelligence needs.
With best wishes for 2012!
The Arcas Group and MDOUTLOOK Teams
December 19th, 2011
Through our disease intelligence service, MDoutlook, Arcas has have provided insight and support for several news items since the summer:
* An article was published in the journal Value-Based Cancer Care in August 2011 about the cost implications for novel therapies in the treatment of non-small cell lung cancer (NSCLC). MDoutlook provided key insight on how the US and global community of medical oncologists will shift their management of NSCLC based on new information presented at ASCO 2011.(Article VBCC 08-2011)
* This month OBR published an article featuring immediate market insight delivered by MDoutlook to gauge the clinical impact of the recent FDA decision to revoke marketing authorization of bevacizumab (Avastin®) in HER-2 negative metastatic Breast Cancer. The article can be read here.
MDOUTLOOK, the global oncology intelligence platform, provides crucial insight into the dynamic role of clinicians involved in treating today’s oncology patient. You can read more about MDoutlook here. If you would like to talk to us or schedule a demo, please contact us at info@thearcasgroup.com.
November 23rd, 2011
We are very pleased to welcome Allison Easley to the leadership of The Arcas Group as Director, Account Services. She joins with more than 15 years of experience in servicing the pharmaceutical and biotech industry, in the United States, Europe and other regions.
Allison has used her expertise, insight and deep understanding of all Oncology/hematology tumor types in addition to respiratory medicine, immunology, critical care, and urology to design strategies and activities and meet brand objectives. She has built and utilized a variety of communication, research & media platforms for activities supporting a variety of functions at life science companies, including Commercialization Strategy, Strategic Marketing, Advocacy development, Consulting Activities, Publication Planning, Tactical Planning, Market Research, Medical Education, and Medical Communications.
“I am excited to have Allison join our team. Having worked with her in earlier stages of her career, I continue to be impressed with her high levels of energy, great insight and her dedication to consistently exceed client expectations. She is a great asset to our company and will be instrumental in expanding our relationship with our clients,” says Jan Heybroek, President of The Arcas Group.
“Arcas continues to multiply its revenue and client base through our unwavering commitment to exceed client expectations, which is highlighted by our extremely high retention client rate of 94% and the growth of business per client. Our staff rates amongst the very best in the industry, and it is a real pleasure and privilege to lead the team on the growth path we have followed from the company’s inception. This year alone we have signed on 10 new clients to our roster and have grown the MDOUTLOOK network of cancer physicians to more than 53,000 worldwide.”
November 23rd, 2011
MDOUTLOOK, the global oncology intelligence initiative powered by The Arcas Group, announced results from its 4th Annual Quick Poll research launched immediately following this month’s annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. These Quick Polls expand on previous Quick Polls carried out after the past 3 ASCO annual meetings, and other meetings such American Society of Hematology (ASH) and San Antonio Breast Cancer Symposium (SABCS).
Within one week, 515 cancer treaters in 38 countries responded to 4 individual Quick Polls on melanoma, non-small cell lung cancer (NSCLC), gastrointestinal (GI) cancers and genitourinary (GU) cancers. This is the first market feedback available post-ASCO. Highlights from this significant research study include:
- News from ASCO impacts the entire oncology community. A wide variety of sources are used to learn about the important news from this conference.
- The novel targeted agents vemurafenib and ipilimumab will become the standards of care for malignant melanoma. More than half of all patients with malignant melanoma are expected to receive one if not both of these agents.
- Physicians are excited about the identification of specific NSCLC patient subpopulations who will respond to crizotinib, erlotinib, or MetMab.
- Following their recent regulatory approvals, worldwide use of everolimus and sunitinib for pancreatic neuroendocrine tumors (PNET) will greatly increase.
- There is not a consistent approach to the continued use of anti-angiogenic therapy after progression in stage IV colorectal cancer. Physicians are eagerly awaiting the results of definitive clinical trials which are due in the near future.
- Axitinib is expected to be the most common 2nd line therapy following sunitinib for metastatic renal cell carcinoma (mRCC). However, clinicians use a personalized approach in this setting.
- The clinical landscape for prostate cancer is undergoing a dramatic shift due to a number of new therapeutics; some of which have been recently approved and others still under clinical development.
- The primary clinical trial endpoint reported influences the integration of research into clinical practice.
Members of the MDOUTLOOK Strategy Council reflected that these results “validate the expected change in physician decision-making” and that “it will be interesting to follow-up on a regular basis to track these changes.”
Jan Heybroek, President of The Arcas Group, LLC, which powers MDOUTLOOK commented: “These Quick Polls perfectly demonstrate the ability of MDOUTLOOK to rapidly and in a targeted manner capture the views of validated cancer physicians around the world, and turn this into actionable intelligence.”
Full copies of the 4th Annual MDOUTLOOK Quick Polls from ASCO are available upon request.
About MDOUTLOOK®
MDOUTLOOK was developed with a singular focus: improved understanding of complex diseases leading to better patient care. Over 52,000 medical oncology professionals have opted into a network of their peers through the MDOUTLOOK online platform to share information such as preferred treatment regimens for complex diseases and de-identified patient logs, as well as the factors that play a part in their clinical decision-making.
Physician members of MDOUTLOOK benefit by having access to data on how other clinicians manage difficult cases and how they are adapting to changes in the industry, ranging from the introduction of new drugs or treatment modalities, to the rising costs of certain treatments. For many physicians, MDOUTLOOK also serves as a patient registry.
MDOUTLOOK is guided by a Strategy Council of globally recognized experts: Alexander Eggermont, MD, PhD; Keith Flaherty, MD; William Gradishar, MD; Axel Hauschild, MD; Peter Heald, MD; John Kirkwood, MD; Sagar Lonial, MD; Lauren Pinter-Brown, MD; Joyce O’Shaughnessy, MD; Nicholas Thatcher, MD; and Alan Venook, MD.
MDOUTLOOK delivers life-sciences clients real-time ThoughtLeader and clinician-driven analysis, intelligence and insight into oncology clinical practice (www.thearcasgroup.com/mdoutlook).
About The Arcas Group
The Arcas Group is a strategic life sciences marketing organization with a singular focus: Supporting the commercial success of its clients in the continuum of life sciences marketing – from marketing intelligence to strategy development and implementation – through enhanced connectivity with ThoughtLeaders and Clinicians. MDOUTLOOK is a key offering that is highly valued by its rapidly expanding base of clients.
For more information, please visit The Arcas Group’s website at www.thearcasgroup.com.
CONTACT: Jan A. Heybroek, President, jheybroek@thearcasgroup.com, +1-404-496-4136
July 13th, 2011
MDOUTLOOK and Oncology Business Review, two leading organizations in oncology business intelligence, are hosting a complimentary program exclusively for senior decision-makers in oncology commercialization. You are invited to attend ‘On-College: Insights and Strategies for Fostering Pharma-Physician Relationships in Today’s Dynamic Oncology Marketplace‘.
This inaugural event will take place during ASCO 2011 on Monday, June 6 from 6-8pm at the InterContinental Chicago. This program is by invitation only and intended for commercial oncology professionals interested in improving the value proposition from manufacturers to other cancer stakeholders.
Co-Chairs
Howard S. Hochster, M.D., Associate Director, Yale Cancer Center and Professor of Medicine, Yale School of Medicine
Michael G. King, Jr., Senior Vice President of Corporate Development and Communication, ZIOPHARM Oncology, Inc.
Moderator
Don Sharpe, Publisher, OBR
Panel Discussion
Jan A. Heybroek, President, The Arcas Group & MDOUTLOOK
Howard S. Hochster, M.D., Associate Director, Yale Cancer Center and Professor of Medicine, Yale School of Medicine
Don Sharpe, Publisher, OBR
Michael G. King, Jr., Senior Vice President of Corporate Development and Communication, ZIOPHARM Oncology, Inc.
Please download our printable invitation and email us at event@mdoutlook.com if you or any of your colleagues would like to attend.
We look forward to seeing you in Chicago!
Kind regards,
Jan Heybroek
President, The Arcas Group & MDOUTLOOK
May 27th, 2011
Previous Posts
